The advent of BCR-ABL tyrosine kinase inhibitors (TKI) was a big breakthrough in the treatment of patients with CML, improving their outcomes and quality of life. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.